-DOCSTART- -X- O
Muscle -X- _ B-Intervention
wasting -X- _ I-Intervention
is -X- _ O
one -X- _ O
of -X- _ O
the -X- _ O
main -X- _ O
features -X- _ O
of -X- _ O
cancer -X- _ B-Patient
cachexia -X- _ I-Patient
, -X- _ O
a -X- _ O
multifactorial -X- _ O
syndrome -X- _ O
frequently -X- _ O
occurring -X- _ O
in -X- _ O
oncologic -X- _ B-Patient
patients. -X- _ I-Patient
The -X- _ O
onset -X- _ O
of -X- _ O
cachexia -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
reduced -X- _ O
tolerance -X- _ O
and -X- _ O
response -X- _ O
to -X- _ O
antineoplastic -X- _ O
treatments -X- _ O
, -X- _ O
eventually -X- _ O
leading -X- _ O
to -X- _ O
clinical -X- _ O
conditions -X- _ O
that -X- _ O
are -X- _ O
not -X- _ O
compatible -X- _ O
with -X- _ O
survival. -X- _ O
Among -X- _ O
the -X- _ O
mechanisms -X- _ O
underlying -X- _ O
cachexia -X- _ O
, -X- _ O
protein -X- _ B-Intervention
and -X- _ I-Intervention
energy -X- _ I-Intervention
dysmetabolism -X- _ I-Intervention
play -X- _ O
a -X- _ O
major -X- _ O
role. -X- _ O
In -X- _ O
this -X- _ O
regard -X- _ O
, -X- _ O
several -X- _ O
potential -X- _ O
treatments -X- _ O
have -X- _ O
been -X- _ O
proposed -X- _ O
, -X- _ O
mainly -X- _ O
on -X- _ O
the -X- _ O
basis -X- _ O
of -X- _ O
promising -X- _ O
results -X- _ O
obtained -X- _ O
in -X- _ O
preclinical -X- _ O
models. -X- _ O
However -X- _ O
, -X- _ O
at -X- _ O
present -X- _ O
, -X- _ O
no -X- _ O
treatment -X- _ O
yet -X- _ O
reached -X- _ O
validation -X- _ O
to -X- _ O
be -X- _ O
used -X- _ O
in -X- _ O
the -X- _ O
clinical -X- _ O
practice -X- _ O
, -X- _ O
although -X- _ O
several -X- _ O
drugs -X- _ O
are -X- _ O
currently -X- _ O
tested -X- _ O
in -X- _ O
clinical -X- _ O
trials -X- _ O
for -X- _ O
their -X- _ O
ability -X- _ O
to -X- _ O
improve -X- _ O
muscle -X- _ O
metabolism -X- _ O
in -X- _ O
cancer -X- _ O
patients. -X- _ O
Along -X- _ O
this -X- _ O
line -X- _ O
, -X- _ O
the -X- _ O
results -X- _ O
obtained -X- _ O
in -X- _ O
both -X- _ O
experimental -X- _ O
and -X- _ O
clinical -X- _ O
studies -X- _ O
clearly -X- _ O
show -X- _ O
that -X- _ O
cachexia -X- _ O
can -X- _ O
be -X- _ O
effectively -X- _ O
approached -X- _ B-Outcome
by -X- _ I-Outcome
a -X- _ I-Outcome
multidirectional -X- _ I-Outcome
strategy -X- _ I-Outcome
targeting -X- _ I-Outcome
nutrition -X- _ I-Outcome
, -X- _ I-Outcome
inflammation -X- _ I-Outcome
, -X- _ I-Outcome
catabolism -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
inactivity -X- _ I-Outcome
at -X- _ O
the -X- _ O
same -X- _ O
time. -X- _ O
In -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
, -X- _ O
approaches -X- _ O
aimed -X- _ O
to -X- _ O
modulate -X- _ B-Intervention
muscle -X- _ I-Intervention
metabolism -X- _ I-Intervention
in -X- _ O
cachexia -X- _ O
will -X- _ O
be -X- _ O
reviewed -X- _ O
. -X- _ O

